Adeptrix Closes Series A Financing to Commercialize BAMS™ Bioanalytical Reagents for Life Science Research

Adeptrix Corp, the developer of advanced bioanalytical tools based on its proprietary BAMS™ (Bead Assisted Mass Spectrometry) platform technology, today announced the closing of its Series A investment round with Bruker Corporation as a new minority investor. The proceeds will go toward accelerating commercialization of multiple BAMS products and establishing custom BAMS assay development service for pharma, clinical, and food-science customers. Adeptrix has recently entered into several research collaborations, leveraging its unique approach, to develop tools for accurate, rapid and easy-to-use COVID-19 diagnostics. The Adeptrix BAMS assay will be used for the direct detection of SARS-CoV-2 virus infection by targeting viral proteins such as the spike glycoprotein and the nucleocapsid protein, and it also can be expanded to enable routine use of MALDI MS for other viruses to advance future clinical virology research. Adeptrix’ BAMS technology is a multiplexed immunoassay platform for targeted analysis of proteins and protein fragments by MALDI-TOF mass spectrometry. By measuring each immunoassay in thousands of channels using MALDI mass spectrometry, BAMS delivers greater analytical precision and specificity for drug discovery, diagnostics, and food safety testing applications. BAMS allows detection of protein biomarkers that have remained inaccessible to the conventional immunoassays and PCR-mediated tests, including post-translational modifications, point mutations and protein degradation products that play a key role in developmental and disease biology. Adeptrix Corp is a developer and manufacturer of analytical reagents and assays that are based on the company’s proprietary platform technology termed Bead Assisted Mass Spectrometry (BAMS). BAMS™ is an innovative and powerful analytical platform that allows immunoassays to be measured by MALDI mass spectrometry for rapid, precise and sensitive target analyte detection. The BAMS platform technology is both multiplexed (capable of measuring multiple target analytes in a single assay) and high-throughput (capable of measuring hundreds to thousands of assays per day), making it amenable for a wide range of bio-analytical applications in drug development, basic research and clinical diagnostics. The current inventory of BAMS reagents have been configured for protein analysis in the fields of neurology, oncology and epigenetics. Over 30 assays are planned for release in Q1 2021. Adeptrix will develop and commercialize BAMS assay kits for virology research and clinical diagnostics, both directly and via its strategic partners’ worldwide sales and marketing teams. The assays will be developed specifically to leverage the large installation base of MALDI instruments in Pharma and Academia.
（以上内容由医药魔方AI生成）